Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
Jörn Aldag, who has over 20 years of leadership experience in the life sciences industry, including CEO of gene therapy pioneer uniQure, tells Scrip that the research carried at the world-class Italian research institute SR-Tiget.
Also, NeuBase Therapeutics has secured a new chief operating officer and Amgen has named a new vice president-finance/chief accounting officer.
AnaptysBio secures new chief financial officer, while Tarsus Pharmaceuticals has a new chief operating officer.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Executives On The Move: Boehringer Announces US Promotion, Immatics Chooses A CMO And DalCor Pharma Fills C-Suite Commercial Post
Boehringer Ingelheim announces its BI Pharma president to take helm from retiring US country managing director and chief executive officer. Immunotherapeutics developer Immatics Biotechnologies chooses GSK cell therapy head as CMO, and precision medicine firm DalCor Pharmaceuticals picks a chief commercial officer.
Executives On The Move: Clinical Positions Filled At Gilead, Sanifit and Spectrum, And Ferring Pharma US Officer Is Promoted
Anti-viral pharma Gilead Sciences, vascular calcification treatment firm Sanifit and hematology and oncology drug developer Spectrum Pharmaceuticals each select a new VP, clinical development. Also, to oversee its group in the US, multinational Ferring Pharmaceuticals promotes its US chief commercial officer to president.
Executives On The Move: Ipsen Decides On New Leader, A CSO for 4P-Pharma And A CFO During Transition for Histogen
Paris, France-based Ipsen decides on a Sanofi Pasteur exec for CEO and Roche Institute head joins cancer and inflammatory therapy company 4P-Pharma as CSO. Meanwhile, regenerative medicine firm Histogen brings on a new CFO during its transition to a public company.
Arix Biosciences has unveiled three significant changes to the organization, including the appointment of Christian Schetter as co-managing director, which the healthcare-focused venture capitalist hopes will keep its impressive record of biotech investments on track.
Exits from Pfizer and Gilead as executives move to Oligomerix Inc. and Pandion Therapeutics, respectively, while chief medical officers are appointed at Exicure and Larimar Therapeutics Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.